DGX
Quest DiagnosticsNYSEHealth CareDiagnostics & ResearchSnapshot 2026-05-08
As of May 8, 2026, DGX has a composite score of 20.1 and a signal label of "mild favorable." The score is influenced by a medium confidence level of 77.4 and reflects various factors, including a macro score of 31.5 and a management score of 64.4. The analysis is provisional, indicating that the data may be subject to change.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.09
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $2.86 → $2.82 (-1.4% / 30d). 2 raised, 9 cut, 14 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 50% of analysts rate Buy.
2 PT revisions / 30d. Avg target 9.7% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
3 material events in the last 24 months — top 3 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase revenue growthgrowthbehind14% progress
5/4: “Management has consistently emphasized the need to increase revenue growth.”
Why this status
Stated in 2 of last 2 quarters. Revenue declined from $2.62B in 2024-Q4 to $1.93B in 2025-Q4, indicating limited progress in achieving revenue growth. Management's focus on increasing revenue growth has not yet translated into financial improvement.
- 2.Enhance EPS growthgrowthbehind14% progress
5/4: “Management has reiterated the goal of enhancing EPS growth.”
Why this status
Stated in 2 of last 2 quarters. EPS declined from $2.03 in 2024-Q2 to $1.72 in 2025-Q1, showing limited progress in enhancing EPS growth. Despite management's focus, the financials reflect a declining trend.
- 3.Manage capital expenditurescapital allocationmixed44% progress
5/4: “Management has emphasized disciplined capital expenditure management.”
Why this status
Stated in 2 of last 2 quarters. Capex guidance for 2026 is approximately $550M, indicating management's commitment to disciplined capital expenditure management. However, the financials do not yet reflect significant changes in capex levels.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 25%; 252d 23%.
Drawdown — Max 1y −11%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.44 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 62/100, drawdown 78/100, beta 44/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase revenue growth
GrowthNew since 2026-05-04Focus on increasing revenue growth through strategic initiatives.
BehindStated in 2 of last 2 quarters. Revenue declined from $2.62B in 2024-Q4 to $1.93B in 2025-Q4, indicating limited progress in achieving revenue growth. Management's focus on increasing revenue growth has not yet translated into financial improvement.
14%CEO/CFO:“Management has consistently emphasized the need to increase revenue growth.”Multiple sourcesSource dated 2026-05-04Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Management has consistently emphasized the need to increase revenue growth.”
- 2025-Q4Multiple sources
“Management has consistently emphasized the need to increase revenue growth.”
- #2
Enhance EPS growth
GrowthNew since 2026-05-04Aim to enhance EPS growth through operational efficiencies and strategic initiatives.
BehindStated in 2 of last 2 quarters. EPS declined from $2.03 in 2024-Q2 to $1.72 in 2025-Q1, showing limited progress in enhancing EPS growth. Despite management's focus, the financials reflect a declining trend.
14%CEO/CFO:“Management has reiterated the goal of enhancing EPS growth.”Multiple sourcesSource dated 2026-05-04Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Management has reiterated the goal of enhancing EPS growth.”
- 2025-Q4Multiple sources
“Management has reiterated the goal of enhancing EPS growth.”
- #3
Manage capital expenditures
Capital allocationNew since 2026-05-04Maintain disciplined capital expenditure management to optimize financial performance.
Behind →MixedStated in 2 of last 2 quarters. Capex guidance for 2026 is approximately $550M, indicating management's commitment to disciplined capital expenditure management. However, the financials do not yet reflect significant changes in capex levels.
44%CEO/CFO:“Management has emphasized disciplined capital expenditure management.”Multiple sourcesSource dated 2026-05-04Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Management has emphasized disciplined capital expenditure management.”
- 2025-Q4Multiple sources
“Management has emphasized disciplined capital expenditure management.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Around its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
DGX Quest Diagnostics | +20 | full | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-04-21)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2117d agoItem 2.02
Results of Operations and Financial Condition On April 21, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
earnings preannouncementneutralscore 44 - 2026-05-017d agoItem 8.01
Other Events On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million…
capital allocationneutralscore 44 - 2026-03-121mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. The Board appointed Mr. Wentworth to serve on the Board’s Compen…
executive changeneutralscore 21 - 2026-02-102mo agoItem 2.02
Results of Operations and Financial Condition On February 10, 2026, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
earnings preannouncementneutralscore 9 - 2026-02-102mo agoItem 8.01
Other Events On February 10, 2026, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per share. The 7.5% increase in the quarterly dividend is effective with the dividend payable on April 20, 2026 to shareholders of record of the Company’s common stock on A…
capital allocationpositivescore 7
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.